


 Cite this: *RSC Adv.*, 2022, 12, 33175

 Received 8th August 2022
 Accepted 23rd September 2022

DOI: 10.1039/d2ra04958a

rsc.li/rsc-advances

An intramolecular hydrogen bond-promoted “green” Ugi cascade reaction for the synthesis of 2,5-diketopiperazines with anticancer activity†

 Jie Li, Jiu Hong Huang, Jing Ya Wang, Zhi Gang Xu, Zhong Zhu Chen and Jie Lei *

We report a “green chemistry”-based Ugi cascade reaction to furnish a series of 2,5-diketopiperazines (through nucleophilic attack of amides upon ketones in Ugi adducts) at moderate-to-good yields. Investigation with the MTT assay revealed compound (\pm) **5c** to exhibit potent anticancer activities against acute myeloid leukaemia (MV411; IC_{50} = 1.7 μ M) and acute T lymphocyte leukaemia (Jurkat; IC_{50} = 5.7 μ M) cell lines.

“Green chemistry” concepts can guide advanced syntheses in organic chemistry.¹ The four-component Ugi reaction (U-4CR) perfectly matches with the concepts of green chemistry. U-4CR employs four commercially available reagents to furnish dipeptide-like products and has been used widely to construct diverse heterocyclic scaffolds.² Among nitrogen derivatives, a cyclic dipeptide (2,5-diketopiperazine) is an important scaffold in medicinal chemistry and drug discovery. In this scaffold, various substituents exhibit numerous medically relevant properties, such as the: potent antimalarial activity of Diatretol I³ and its relevant scaffold of lepidamides II;⁴ antibacterial activity of thaxtomins A III;⁵ antibiotic activity of bicyclomyacin IV⁶ as well as its activity towards microtubule depolymerization V,⁷ 5HT ligands VI⁸ and radical scavenging VII⁹ (Fig. 1).

Therefore, 2,5-diketopiperazine has been considered to be a “privileged” scaffold in drug discovery. Efficient strategies for rapid construction of structurally diverse scaffolds have been demanded. Some methods related to this particular cyclic dipeptide have been published. One method involves using functionalized piperazinones as starting reagents to provide a structural elaboration of the piperazine-2,5-dione motif.¹⁰ Another method involves using 2-aminohydrazide or an amino acid as starting materials for the preparation of diketopiperazines *via* multi-step sequences (Scheme 1a).¹¹ Recently, an acid-catalysed-reaction was applied to facilitate monodehydro-2,5-diketopiperazine (DKP), which was limited to *N*-a-ketoacyl amino acid amides (Scheme 1b).¹² Later on, an acyclic compound was subjected to direct base-mediated keto-amide cyclization to afford DKPs in a 10 : 1 dr, but only one example






Fig. 1 Bioactive derivatives of 2,5-diketopiperazine.

Previous works for the synthesis of 2,5-diketopiperazine



(d) This work



Scheme 1 Reported and designed synthetic routes of 2,5-diketopiperazines.

College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts and Sciences, Chongqing 402160, China

† Electronic supplementary information (ESI) available. CCDC 2009028. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d2ra04958a>




was reported.¹³ The transformation of amino-acid substrates to 2,5-diketopiperazine was reported by Parac-Vogt and co-workers, which was conducted in the presence of the Zr/Wells-Dawson 2:2 complex in dimethyl sulfoxide (Scheme 1c).¹⁴ Revuelta and co-workers stated that the replacement of a ketone with an aromatic aldehyde as carbonyl compounds cannot be tolerated *via* isocyanide-based multicomponent reactions (iMCRs),¹⁵ but desired compounds were not detected using Ugi adducts as starting materials under basic conditions. Even though there were several examples in which Ugi adducts could be converted to 2,5-diketopiperazine scaffolds, only a few compounds were synthesized and a narrow substrate scope confined the applicability of synthetic methodologies.

We were interested in the development of new cascade reactions based on iMCRs. Hence, we analysed the sequence mechanism employed to construct pyrrolopyridinones, indoline-piperidinones and 4-imidazolidinones by our research team.¹⁶ Ugi adducts were formed using a mixture of benzoylformic acid, ethyl glyoxylate, isocyanide and an aromatic amine (containing an electron-withdrawing group). We postulated that, in this Ugi core, the reaction started with nucleophilic attack of a carbanion to afford the four-membered azetidion-2-one ring (Scheme 2, path A).¹⁷ In contrast, secondary amides would be deprotonated and used as nucleophiles to attack the α -ketone, thereby resulting in a 2,5-diketopiperazine ring. We assumed that replacement of ethyl glyoxylate with an aromatic aldehyde reduced the reactivity of the nucleophilic carbon. In this case, transformation of the four-member ring intermediate was inhibited, which promoted the nucleophilic attack of the amide to access 2,5-diketopiperazines (Scheme 2, path B). We wondered if the two nucleophilic sites (secondary amide and α -carbon) in this unique reaction had a distinct pathway to finish cyclization through a Ugi sequence.¹⁸ Following this idea, we herein present a base-promoted approach to the synthesis of 2,5-diketopiperazines. This new method broadens the substrate scope of a microwave-assisted one-pot protocol under solvent-free conditions (Scheme 1d). Importantly, the principles of green chemistry and absence of solvents carry several advantages over a traditional organic process: simple operation, less toxic and hazardous chemicals and an accelerated reaction rate.¹⁹

To check our hypothesis, a highly functionalized precursor C was constructed readily through the Ugi four-component reaction of benzoylformic acid **1a**, tryptamine **2a**, benzyl isocyanide **3a** and benzaldehyde **4a** (Table 1). The protic solvent in the


reaction could dissolve the substrates thoroughly, but could also polarize imines to access Ugi products in good yields. Inspired by these findings, we attempted to construct a one-pot procedure to obtain the final products. After the Ugi reaction had been completed, the crude Ugi adduct C was treated under certain reaction conditions. Subsequently, the protic solvent of methanol (MeOH) was selected to evaluate the effect of bases. Screening the organic base and inorganic base revealed that 2.0 equiv. of diisopropanolamine (DIPA) showed promising results and gave the desired product in MeOH with a yield of 31%. To further increase the yield of (\pm) **5a**, we switched our attention to solvent effects, and different solvents were assessed. *n*-BuOH (*n*-butanol) was a powerful solvent under microwave irradiation at 100 °C for 20 min, which provided a much higher yield than MeOH (57%, entry 11). To our delight, the Ugi adduct C was obtained by removing the solvent. Then, 2.0 equiv. of DIPA was added directly to the mixture, followed by microwave irradiation at 100 °C for 20 min. The final product (\pm) **5a** was isolated with 53% yield. In addition, a solvent-free strategy has been implemented widely and attracted considerable attention recently. This is an alternative, sustainable route that could overcome the drawbacks of conventional methods of organic synthesis, such as tedious workup procedures and generation of large amounts

Table 1 Optimization of reaction conditions^a



| Entry | Base | Solvent | Temp. (°C) | Time (min) | Yield ^b (%) |
|-------|---------------------------------|----------------|---------------|------------|------------------------|
| 1 | DBU | MeOH | MW 100 | 20 | NR |
| 2 | TEA | MeOH | MW 100 | 20 | 27 |
| 3 | DABCO | MeOH | MW 100 | 20 | 19 |
| 4 | DIPEA | MeOH | MW 100 | 20 | 22 |
| 5 | DIPA | MeOH | MW 100 | 20 | 31 |
| 6 | NaHCO ₃ | MeOH | MW 100 | 20 | NR |
| 7 | Na ₂ CO ₃ | MeOH | MW 100 | 20 | NR |
| 8 | NaOH | MeOH | MW 100 | 20 | NR |
| 9 | Na ^t OBu | MeOH | MW 100 | 20 | NR |
| 10 | DIPA | EtOH | MW 100 | 20 | 32 |
| 11 | DIPA | <i>n</i> -BuOH | MW 100 | 20 | 45 |
| 12 | DIPA | <i>i</i> -PrOH | MW 100 | 20 | 26 |
| 13 | DIPA | DMF | MW 100 | 20 | NR |
| 14 | DIPA | Toluene | MW 100 | 20 | NR |
| 15 | DIPA | MeCN | MW 100 | 20 | 15 |
| 16 | DIPA | — | MW 100 | 20 | 53 |
| 17 | DIPA | — | MW 130 | 20 | 62 |
| 18 | DIPA | — | MW 160 | 20 | 71 |
| 19 | DIPA | — | MW 180 | 20 | Complex |

^a The reaction was carried out with **1a** (0.3 mmol), **2a** (0.3 mmol), **3a** (0.3 mmol) and **4a** (0.3 mmol) in MeOH at room temperature. After the solvent had evaporated, the crude product C was treated directly with a base (2.0 equiv.) to afford (\pm) **5a**. DBU = 1,8-diazabicycloundec-7-ene; TEA = triethylamine; DABCO = 1,4-diazabicyclo[2.2.2]octane; DIPEA = *N,N*-diisopropylethylamine; DIPA = diisopropanolamine; DMF = dimethylformamide; MW = microwave. ^b Isolated yield.



Scheme 2 Nucleophilic attack of carbanion (path A) or secondary amide (path B).




of solvent waste. To pursue green chemistry, we increased the reaction temperature from 100 °C to 180 °C, and a satisfactory yield (71%) of the target compound was obtained under microwave irradiation at 160 °C for 20 min (entry 18). The optimized reaction condition was determined to be 2.0 equiv. DIPA without a solvent under microwave irradiation at 160 °C for 20 min.

Upon determination of the optimized reaction condition, we evaluated the scope of microwave-promoted Ugi cascades for the synthesis of 2,5-diketopiperazines. This green Ugi cascade worked well and there was no distinct difference in the yield of desired products. The structure of the isolated compound (\pm) **5a** (CCDC 2009028) was confirmed unequivocally by X-ray crystallography (Scheme 3). Various benzaldehydes were used as aldehyde sources to furnish Ugi adducts that were converted efficiently to the corresponding products. Structures (\pm) **5b–f** suggested that aldehydes containing electron-withdrawing groups (F, Br, Cl, NO₂) provided final yields of compounds from 60% to 70%. Unsurprisingly, aldehydes containing electron-donating groups (*e.g.*, Me, MeO, *t*-Bu) could be tolerated well, and afforded yields from 79% to 83% ((\pm) **5g–i**). These results were consistent with data from our previous work^{16,17} and suggested that the nucleophilic attack occurred between the carbanion and ketone of benzoylformic acid. For the isocyanide moiety, commercially available 4-methoxyl benzyl isocyanide was investigated to broaden the substrate scope and evaluate reaction compatibility. The yields from reactions (\pm) **5j–m** did not decrease dramatically. Crude Ugi adducts with a 4-


methoxyl benzoylformic acid moiety and 4-bromo benzoylformic acid moiety were conducted under a standard condition to generate final compounds (\pm) **5n** and (\pm) **5o** with good yields. A substrate containing a heterocycle furan was also processed well; a one-pot isolated yield of 70% was achieved for (\pm) **5p** *via* a post-Ugi cascade sequence under a solvent-free condition.

To gain further insights into the reaction mechanism, several control experiments were conducted (Scheme 4). The highly functionalized Ugi adduct **6** was synthesized using phenethylamine as the amine source. Regrettably, the corresponding 2,5-diketopiperazine analogue (\pm) **7** was not obtained under identical conditions. Subsequently, we replaced tryptamine with benzylamine or aniline to facilitate model substrates. As anticipated, desired products were not detected. These data suggested that the N–H of the indole moiety was essential to activate the ketone for the nucleophilic addition reaction (Scheme 4a). Based on control experiments and previous works, the mechanism of this green synthesis was proposed (Scheme 4b). Adduct **D** were generated *in situ* using methanol as the solvent at room temperature. Due to steric hindrance, the NH group of the indole exhibited a strong interaction with the ketone of the acid moiety to start the nucleophilic addition reaction through key intermediate **E**. Deprotonated amide **F** attacked the activated ketone to achieve the final compound (\pm) **5**.

Biological application of 2,5-diketopiperazines was investigated for development of a lead drug compound. Synthesized compounds were evaluated for their *in vitro* toxicity against the human cancer cell lines DU145, PC3, MV411 and Jurkat by the MTT assay (Table 2). Gladly, compound (\pm) **5e** showed higher inhibitory activity against the prostate-cancer cell lines DU 145 and PC3 at 10 μ M (Fig. 2a and b). In contrast, compound (\pm) **5c** displayed the highest toxicity against myeloid leukaemia cell lines (Fig. 2c and d). Compound (\pm) **5c** had potent inhibitory activity against acute myeloid leukaemia (MV411, IC₅₀ = 1.7 μ M) and acute T lymphocyte leukaemia (Jurkat, IC₅₀ = 5.7 μ M) lines (ESI[†]). Compound (\pm) **5c** dose-dependently induced cell-



Scheme 3 Scope of 2,5-diketopiperazines.



Scheme 4 Control experiments and proposed reaction mechanism.



Table 2 Cell viability of (\pm) 5

| Entry | Name | DU145 | MV4-11 | Jurkat | PC3 |
|-------|-------------------|--------|--------|--------|-------|
| 1 | (\pm) 5a | 75.50 | 15.02 | 53.19 | 61.36 |
| 2 | (\pm) 5b | 62.58 | 37.09 | 33.85 | 25.48 |
| 3 | (\pm) 5c | 58.71 | 8.88 | 27.31 | 59.60 |
| 4 | (\pm) 5d | 54.40 | 10.02 | 30.11 | 54.07 |
| 5 | (\pm) 5e | 26.30 | 21.08 | 30.94 | 18.74 |
| 6 | (\pm) 5f | 100.78 | 17.28 | 43.14 | 66.43 |
| 7 | (\pm) 5g | 91.91 | 19.08 | 63.80 | 97.94 |
| 8 | (\pm) 5h | 74.02 | 15.76 | 37.18 | 78.48 |
| 9 | (\pm) 5i | 64.03 | 22.65 | 34.39 | 57.54 |
| 10 | (\pm) 5j | 93.17 | 18.92 | 40.33 | 93.37 |
| 11 | (\pm) 5k | 107.35 | 52.87 | 37.04 | 63.43 |
| 12 | (\pm) 5l | 68.02 | 17.05 | 47.33 | 67.17 |
| 13 | (\pm) 5m | 101.39 | 24.95 | 75.16 | 94.37 |
| 14 | (\pm) 5o | 101.35 | 11.96 | 43.29 | 76.40 |
| 15 | (\pm) 5p | 93.52 | 33.11 | 45.21 | 58.73 |
| 16 | THZ1 ^a | 69.45 | 19.23 | 16.24 | 82.91 |

^a THZ1 is a selective inhibitor of CDK7.




Fig. 2 MTT assay for synthesized compounds. Cells were treated with compounds (\pm) 5a–p at 10 μ M for 24 h, respectively, and cell viability was measured. Data are the mean \pm SD of three independent experiments. Each experiment was conducted in sextuplicate.

cycle arrest and apoptosis in mv411 cells (Fig. 2e and f; ESI[†]). Compound (\pm) 5c could be a promising lead compound for selective treatment of acute myeloid leukaemia. Our previous study on the synthesis of maleimide derivatives using scaffold C as a starting reagent revealed them to have broad-spectrum anticancer activity against 12 screened cancer cell lines.¹⁷ The

newly obtained 2,5-diketopiperazines in the present study revealed selectivity against myeloid leukaemia cells (Fig. 2). To measure the cytotoxicity of these compounds, we treated a normal adult prostatic epithelial cell line (PNT1A) with these compounds at a concentration of 10 μ M: cell viability was not affected.

Conclusions

Highly functionalized Ugi adducts synthesized using tryptamine, isocyanides, glyoxylic acids and aldehydes as starting materials were subjected to a solvent-free condition. A series of 2,5-diketopiperazines was provided with good yields through an intramolecular hydrogen bond-promoted one-pot procedure. Remarkably, the products possessed potent anticancer activity *in vitro* according to the MTT assay. An in-depth study to discover the mechanism of action of compounds is underway. This green chemistry-based process provides opportunities for designing and synthesizing many compounds which may have medicinal applications.

Ethical statement

The Laboratory Animal Welfare and Ethics Committee of Chongqing University of Arts and Sciences approved (CQWLDF0011) the study protocol on 11 March 2022. Experiments were conducted in compliance with relevant laws or guidelines set by the Chinese government.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors thank the Science and Technology Research Program of Chongqing Municipal Education Commission (KJQN201801321, KJQN202101340, KJZD-M201801301), Natural Science Foundation Project of CQ CSTSC (cstc2018jszxcydzX0023, cstc2021jcyj-bshX0242) and Chongqing University of Arts and Sciences: Program for Talents Introduction (R2021FYX05). We also thank H. Z. Liu for obtaining LC/MS, HRMS and NMR data.

Notes and references

- (a) Y. Gu, *Green Chem.*, 2012, **14**, 2091–2128; (b) D. B. Ramachary and S. Jain, *Org. Biomol. Chem.*, 2011, **9**, 1277–1300; (c) R. U. Gutierrez, H. C. Correa, R. Bautista, J. L. Vargas, A. V. Jerezano, F. Delgado and J. Tamariz, *J. Org. Chem.*, 2013, **78**, 9614–9626; (d) B. Jiang, S. J. Tu, P. Kaur, W. Wever and G. Li, *J. Am. Chem. Soc.*, 2009, **131**, 11660–11661; (e) A. Kumar and S. Sharma, *Green Chem.*, 2011, **13**, 2017–2020; (f) X. Wang, S.-Y. Wang and S.-J. Ji, *Org. Lett.*, 2013, **15**, 1954–1957; (g) M. Jereb and V. Dejan, *Org. Biomol. Chem.*, 2013, **11**, 1978–1999; (h) H. Sardon, A. C. Engler, J. M. W. Chan, D. J. Coady, J. M. O'Brien,



- D. Mecerreyes, Y. Y. Yang and J. L. Hedrick, *Green Chem.*, 2013, **15**, 1121–1126; (i) S. Yan, Y. Chen, L. Liu, N. He and J. Lin, *Green Chem.*, 2010, **12**, 2043–2052.
- 2 (a) Z. Xu, F. D. Moliner, A. P. Cappelli and C. Hulme, *Angew. Chem., Int. Ed.*, 2012, **51**, 8037–8040; (b) J. Lei, J.-P. Meng, D.-Y. Tang, B. Frett, Z.-Z. Chen and Z.-G. Xu, *Mol. Diversity*, 2018, **22**, 503–516.
- 3 A. Ishiyama, R. Hokari, K. Nonaka, T. Chiba, H. Miura, K. Otoguro and M. Iwatsuki, *J. Antibiot.*, 2021, **74**, 266–268.
- 4 (a) X. L. Chen, M. Wu, H. H. Ti, X. Y. Wei and T. H. Li, *Helv. Chim. Acta*, 2011, **94**, 1426–1432; (b) S. Takahashi, A. Kimishima, T. Hirose, T. Yamada, A. Sugawara, T. Shirahata, Y. Noguchi, M. Iwatsuki, R. Hokari, A. Ishiyama, Y. Kobayashi and T. Sunazuka, *Tetrahedron Lett.*, 2021, **67**, 152895–152906.
- 5 (a) R. R. King, C. H. Lawrence, M. C. Clark and L. A. Calhoun, *J. Chem. Soc., Chem. Commun.*, 1989, **13**, 849–856; (b) J. P. Bourgault, A. R. Maddirala and P. R. Andreama, *Org. Biomol. Chem.*, 2014, **12**, 8125–8127.
- 6 S. Meng, W. Han, J. Zhao, X. H. Jian, H. X. Pan and G. L. Tang, *Angew. Chem., Int. Ed.*, 2018, **57**, 719–723.
- 7 K. Kanoh, S. Kohno, T. Asari, T. Harada, J. Katada, M. Muramatsu, H. Kawashima, H. Sekiya and I. Uno, *Bioorg. Med. Chem. Lett.*, 1997, **22**, 2847–2856.
- 8 (a) C. Labriere, G. Cervin, H. Pavia, J. H. Hansen and J. Svenson, *Mar. Biotechnol.*, 2021, **23**, 904–916; (b) E. K. Olsen, E. Hansen, L. W. K. Moodie, J. Isaksson, K. Sepčić, M. Cergolj, J. Svenson and J. H. Andersen, *Org. Biomol. Chem.*, 2016, **14**, 1629–1640.
- 9 C. B. Cui, H. Kakeya, G. Okada, R. Onose and H. Osada, *J. Antibiot.*, 1996, **49**, 527–533.
- 10 (a) Y. Yamazaki, K. Tanaka, B. Nicholson, G. Deyanat-Yazdi, B. Potts, T. Yoshida, A. Oda, T. Kitagawa, S. Orikasa, Y. Kiso, H. Yasui, M. Akamatsu, T. Chinen, T. Usui, Y. Shinozaki, F. Yakushiji, B. R. Miller, S. Neuteboom, M. Palladino, K. Kanoh, G. K. Lloyd and Y. Hayashi, *J. Med. Chem.*, 2012, **55**, 1056–1071; (b) T. W. Giessen and M. A. Marahiel, *Front. Microbiol.*, 2015, **6**, 785–795.
- 11 (a) M. S. Lee, Y. Kim, E. Youk and Y. S. Park, *Bull. Korean Chem. Soc.*, 2016, **37**, 981–985; (b) G. Simon, C. Bérubé, N. Voyer and D. Grenier, *Bioorg. Med. Chem.*, 2019, **27**, 2323–2329; (c) A. D. Borthwick, *Chem. Rev.*, 2012, **7**, 3641–3716.
- 12 Y. Yamazaki, Y. Mori, A. Oda, Y. Okuno, Y. Kiso and Y. Hayashi, *Tetrahedron*, 2009, **65**, 3688–3694.
- 13 J. P. Bourgault, A. R. Maddirala and P. R. Andreama, *Org. Biomol. Chem.*, 2014, **12**, 8125–8127.
- 14 F. Azambuja and T. N. Parac-Vogt, *ACS Catal.*, 2019, **9**, 10245–10252.
- 15 C. Faggi, A. G. Neo, S. Marcaccini, G. Menchi and J. Revuelta, *Tetrahedron Lett.*, 2008, **49**, 2099–2107.
- 16 (a) Y. Li, J. Lei, Z.-Z. Chen, D.-Y. Tang, H. Yuan, M. Wang, J. Zhu and Z.-G. Xu, *Eur. J. Org. Chem.*, 2016, **2016**, 5770–5774; (b) J. Lei, G.-T. Song, Y.-F. Luo, D.-Y. Tang, W. Yan, H. Li, Z.-Z. Chen and Z.-G. Xu, *Org. Chem. Front.*, 2020, **7**, 737–741; (c) G.-T. Song, C.-H. Qu, J. Lei, W. Yan, D.-Y. Tang, H. Li, Z.-Z. Chen and Z.-G. Xu, *Adv. Synth. Catal.*, 2020, **362**, 4084–4091.
- 17 J. Lei, G.-T. Song, L.-J. He, Y.-F. Luo, D.-Y. Tang, H.-K. Lin, B. Frett, H. Li, Z.-Z. Chen and Z.-G. Xu, *Chem. Commun.*, 2020, **56**, 2194–2197.
- 18 A. L. Kennedy, A. M. Fryer and J. A. Josey, *Org. Lett.*, 2002, **4**, 1167–1170.
- 19 (a) M. A. P. Martins, C. P. Frizzo, D. N. Moreira, L. Buriol and P. Machado, *Chem. Rev.*, 2009, **109**, 4140–4182; (b) G. W. V. Cave, C. L. Raston and J. L. Scott, *Chem. Commun.*, 2001, 2159–2169; (c) C. Cheng, B. Jiang, S.-J. Tu and G. Li, *Green Chem.*, 2011, **13**, 2107–2115; (d) S. Vidyacharan, A. H. Shinde, B. Satpathi and D. S. Sharada, *Green Chem.*, 2014, **16**, 1168–1175.

